Department of Viroscience, Erasmus Medical Center, Bilthoven, the Netherlands.
Center for Infectious Diseases Research, Diagnostics, and Screening, National Institute of Public Health and the Environment, Bilthoven, the Netherlands.
J Infect Dis. 2017 Dec 19;216(12):1513-1524. doi: 10.1093/infdis/jix520.
The genus Norovirus comprises large genetic diversity, and new GII.4 variants emerge every 2-3 years. It is unknown in which host these new variants originate. Here we study whether prolonged shedders within the immunocompromised population could be a reservoir for newly emerging strains.
Sixty-five fecal samples from 16 immunocompromised patients were retrospectively selected. Isolated viral RNA was enriched by hybridization with a custom norovirus whole-genome RNA bait set and deep sequenced on the Illumina MiSeq platform.
Patients shed virus for average 352 days (range, 76-716 days). Phylogenetic analysis showed distinct GII.4 variants in 3 of 13 patients (23%). The viral mutation rates were variable between patients but did not differ between various immune status groups. All within-host GII.4 viral populations showed amino acid changes at blocking epitopes over time, and the majority of VP1 amino acid mutations were located at the capsid surface.
This study found viruses in immunocompromised hosts that are genetically distinct from viruses circulating in the general population, and these patients therefore may contain a reservoir for newly emerging strains. Future studies need to determine whether these new strains are of risk to other immunocompromised patients and the general population.
诺如病毒属具有较大的遗传多样性,每隔 2-3 年就会出现新的 GII.4 变异株。目前尚不清楚这些新变异株源自哪种宿主。本研究旨在探讨免疫功能低下人群中持续性排毒者是否可能成为新出现株的储存宿主。
回顾性选择了 16 名免疫功能低下患者的 65 份粪便样本。采用定制的诺如病毒全基因组 RNA 诱饵集杂交对分离的病毒 RNA 进行富集,并在 Illumina MiSeq 平台上进行深度测序。
患者的平均排毒时间为 352 天(范围为 76-716 天)。系统进化分析显示,13 名患者中有 3 名(23%)存在不同的 GII.4 变异株。患者之间的病毒突变率存在差异,但在不同免疫状态组之间无差异。所有患者体内的 GII.4 病毒种群随时间推移在阻断表位处出现氨基酸变化,大多数 VP1 氨基酸突变位于衣壳表面。
本研究在免疫功能低下宿主中发现了与普通人群中流行的病毒在遗传上不同的病毒,这些患者可能是新出现株的储存宿主。未来的研究需要确定这些新菌株是否对其他免疫功能低下患者和普通人群构成风险。